Gerard Brophy - Jul 30, 2021 Form 4 Insider Report for Avantor, Inc. (AVTR)

Role: EVP, Biopharma Production
Signature: /s/ Scott Baker, as Attorney-in-Fact
Stock symbol: AVTR
Transactions as of: Jul 30, 2021
Transactions value $: -$1,138,995
Form type: 4
Date filed: 8/2/2021, 04:42 PM
Previous filing: May 21, 2021
Next filing: Jan 5, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AVTR	Common Stock	Options Exercise	$1.88M	+81.1K	+54.31%	$23.20	231K	Jul 30, 2021	Direct
transaction	AVTR	Common Stock	Sale	-$3.02M	-81.1K	-35.19%	$37.24	149K	Jul 30, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVTR	Stock Options (Right to Buy)	Options Exercise	$0	-81.1K	-50%	$0.00	81.1K	Jul 30, 2021	Common Stock	81.1K	$23.21	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $36.65 to $37.51, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above.
F3	Reflects an initial grant of 540,830 stock options in which 40% vested at the time of IPO and the remaining 60% that vests in four equal installments beginning on July 30, 2019.